-
Innovation Ranking
NewInnovation Ranking – Diffusion Pharmaceuticals Inc
Diffusion Pharmaceuticals Inc (Diffusion), formerly Diffusion Pharmaceuticals LLC is a clinical stage biotechnology company. It develops standard of care therapies. The company improves cancer treatments such as radiation therapy and chemotherapy in treatment-resistant solid tumors, including multiple FDA orphan-designated indications. It offers new and small-molecule drugs for regulating the movement of oxygen into tissue and treatment for stroke, treatment- resistant cancerous tumors, glioblastoma multiforme,pancreatic cancer, brain metastases. Diffusion develops trans sodium crocetinate, a synthetic small molecule that improves the diffusion...
-
Product Insights
NewLikelihood of Approval Analysis for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease)
Overview How likely is it that the drugs in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Onureg in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Onureg in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Onureg in Diffuse Large B-Cell Lymphoma Drug Details: Azacitidine (Onureg)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NiKogene in Pediatric Diffuse Intrinsic Pontine Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NiKogene in Pediatric Diffuse Intrinsic Pontine Glioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NiKogene in Pediatric Diffuse Intrinsic Pontine Glioma Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Varlilumab in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Varlilumab in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Varlilumab in Diffuse Large B-Cell Lymphoma Drug Details: Varlilumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Carfilzomib in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Carfilzomib in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Carfilzomib in Diffuse Large B-Cell Lymphoma Drug Details: Carfilzomib (Kyprolis)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Enitociclib in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Enitociclib in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Enitociclib in Diffuse Large B-Cell Lymphoma Drug Details: Enitociclib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tebotelimab in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tebotelimab in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tebotelimab in Diffuse Large B-Cell Lymphoma Drug Details: Tebotelimab (MGD-013)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tocilizumab in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tocilizumab in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tocilizumab in Diffuse Large B-Cell Lymphoma Drug Details: Tocilizumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Olaparib in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Olaparib in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Olaparib in Diffuse Large B-Cell Lymphoma Drug Details: Olaparib...